Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

NCT05595590 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Tislelizumab
RADIATION: Pulse radiation

Sponsor

Tianjin Medical University Cancer Institute and Hospital